|
 |
| LETTER TO THE EDITOR |
|
|
|
| Year : 2013 | Volume
: 45
| Issue : 5 | Page : 536-537 |
| |
Bedaquiline: A new drug approved for treatment of multidrug-resistant tuberculosis
Shashank Deoghare
Department of Pharmacology, Government Medical College, Surat, Gujarat, India
| Date of Web Publication | 6-Sep-2013 |
Correspondence Address:
Shashank Deoghare
Department of Pharmacology, Government Medical College, Surat, Gujarat
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.117765
How to cite this article:
Deoghare S. Bedaquiline: A new drug approved for treatment of multidrug-resistant tuberculosis. Indian J Pharmacol 2013;45:536-7 |
Sir,
The Food and Drug Administration (FDA), on 28 December 2012, granted accelerated approval to SIRTURO™ (bedaquiline) Tablets as a part of combination therapy in adults with multi-drug-resistant TB (MDR-TB). [1] It is the first new anti-TB drug to be approved after 1998 (rifapentine was approved in 1998) and the first anti-TB drug with a novel mechanism of action to be approved after 40 years (rifampicin was approved in 1974). [2] It is also the first to be introduced specifically for the treatment of MDR-TB in combination with other drugs. [1]
MDR-TB is an infection with a strain of Mycobacterium tuberculosis that is resistant to isoniazid and rifampin, the two most potent first-line anti-TB drugs. MDR-TB has emerged as a serious health threat globally. It affected nearly 630,000 people in 2011, and incidence is increasing in many parts of the world. Unlike Drug-sensitive TB (DS-TB), the treatment of MDR-TB is more complex, requires intense chemotherapy, extensive monitoring and is considerably costly. Use of existing less efficacious second-line drugs is associated with greater side-effects. [3]
Bedaquiline, a diarylquinoline, binds to subunit c of mycobacterial ATP synthase (an enzyme essential for the energy production in M. tuberculosis) and inhibits its activity. [4] It is highly selective for mycobacterial ATP synthase enzyme compared to homologous eukaryotic enzyme (Selectivity Index >20 000). Thus, it is less likely to produce target-based toxicity in the host cells. [5] Due to an entirely new mechanism of action, bedaquiline belongs to a novel class of anti-TB compounds. The distinct target and unique mode of action of bedaquiline reduces the potential for cross-resistance with the existing anti-TB drugs. It is active against DS, MDR, Pre-XDR, and XDR strains of M. tuberculosis in vitro. [6]
Bedaquiline is available as 100 mg tablet for oral administration. Its bioavailability is enhanced in presence of food. It is highly plasma protein bound (>99%) and shows tri-exponential decline in plasma concentration with effective half-life of approximately 24-30 hours and terminal half-life (t 1/2 , term) of approximately 4-5 months. It is metabolized by CYP3A4 to N-monodesmethyl metabolite, which is 4-6 times less potent than the parent drug. Enzyme inducers can reduce the efficacy of bedaquiline, whereas enzyme inhibitors can predispose to its adverse reactions. It is eliminated mainly in feces. [7]
Bedaquiline should be administered as directly observed therapy (DOT) along with standard MDR-TB regimen. Recommended dose is 400 mg once daily for 2 weeks followed by 200 mg thrice weekly for 22 weeks. After 24 weeks of bedaquiline therapy, MDR-TB regimen should be continued as per national TB treatment guidelines. [7]
The most common side-effects reported with bedaquiline therapy are nausea (30%), arthralgia (26%), headache (22%), hemoptysis (14%), chest pain (9%), anorexia (7%), and rash (6%). Important cardiovascular adverse effect is QT prolongation. Concurrent use of other QT-prolonging drugs causes additive QT prolongation. Other important adverse effect is elevation of hepatic transaminases, which is moderate and reversible on discontinuation of therapy. [7] There are no clinical data in pediatric patients, adolescents (<18 yrs), and pregnant and lactating women. The safety and efficacy of bedaquiline for treatment of drug-sensitive TB, extra-pulmonary TB, and HIV-infected patients is not established. Therefore, use of bedaquiline is not recommended in these settings. [7]
What Is an Accelerated Approval?
The accelerated approval program allows FDA to approve a drug for treatment of a serious or life-threatening disease on the basis of clinical data establishing the effect of drug on surrogate endpoints that reasonably predict clinical benefit. Thus, patients get earlier access to promising new drugs. However, the company has to conduct further clinical studies to verify efficacy and safety of the drug to get traditional approval from FDA. [8]
The accelerated approval to bedaquiline is based on its effect on surrogate endpoint of time to sputum culture conversion in two phase II clinical trials (C208 and C209). C208 was a randomized, double-blind, placebo-controlled trial with two consecutive but separate stages (stage 1 and 2). In this trial, subjects with sputum smear-positive MDR-TB were assigned to either bedaquiline or placebo along with background regimen of other anti-TB drugs. The primary endpoint of this study was time to sputum culture conversion (SCC) defined as time required for two consecutive negative sputum cultures after start of therapy. The secondary endpoint was culture conversion rate at 24 weeks. Results of C208 demonstrated a median time of 83 days for SCC with bedaquiline combination therapy compared to 125 days in placebo combination therapy. Culture conversion rate at the end of 24 weeks was 79 percent in bedaquiline treatment group compared to 58 percent in the placebo treatment group. In an open label C 209 study, which is still ongoing, sputum smear-positive subjects with MDR-TB received bedaquiline with background regimen of anti-TB drugs (no placebo group). Primary and secondary endpoints were same as previous study. In C209 trial, the median time to SCC was 57 days and a culture conversion rate was 80 percent further supporting the efficacy findings. [9]
Phase III trial of bedaquiline is planned to confirm the efficacy findings from previous phase II clinical trials and to obtain additional safety data. Bedaquiline will get traditional FDA approval if results of phase III trial confirm that the drug actually provides clinical benefit. [9] FDA speculates that bedaquiline has the potential to fulfill an unmet medical need for the treatment of MDR-TB and will reduce the risk of development of resistance to other anti-TB drugs in the standard regimen.
| » References | |  |
| 1. | FDA news release. 2012 Dec 31. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333695.htm [Last accessed on 2013 Feb 15]. 
|
| 2. | National Research Council. Ending neglect: The elimination of tuberculosis in the United States. Washington, DC: The National Academies Press; 2000.
|
| 3. | World Health Organization (WHO). Global Tuberculosis Report 2012. Available from: http://www.who.int/tb/publications/global_report/gtbr12_main.pdf [Last accessed on 2013 Feb 15].
|
| 4. | Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, Willebrords R, et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 2007;3:323-24.
[PUBMED] |
| 5. | Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ, Krab K, Vergauwen K, Guillemont J, et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother 2009;53:1290-2.
|
| 6. | Huitric E, Verhasselt P, Andries K, Hoffner SE. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2007;51:4202-04.
[PUBMED] |
| 7. | U.S. Food and Drug Administration. SIRTURO Prescribing Information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/204384s000lbl.pdf [Last accessed on 2013 Jun 23].
|
| 8. | U.S. Food and Drug Administration. CFR - Code of Federal Regulations Title 21 Part 314 Subpart H. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart = 314andshowFR = 1andsubpartNode = 21:5.0.1.1.4.8 [Last accessed on 2013 June 23].
|
| 9. | U.S. Food and Drug Administration. NDA 204-384 Deputy Division Director Summary Review. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/204384Orig1s000SumR.pdf [Last accessed on 2013 June 23].
|
| This article has been cited by | | 1 |
In-vivo studies on Transitmycin, a potent Mycobacterium tuberculosis inhibitor |
|
| Rajesh Mondal, Azger Dusthackeer V. N., Palaniyandi Kannan, Amit Kumar Singh, Kannan Thiruvengadam, Radhakrishnan Manikkam, Shainaba A. S., Mahizhaveni Balasubramanian, Padmasini Elango, Sam Ebenezer Rajadas, Dinesh Bharadwaj, Gandarvakottai Senthilkumar Arumugam, Suresh Ganesan, Hemanth Kumar A. K., Manjula Singh, Shripad Patil, Jaleel U. C. A., Mukesh Doble, Balagurunathan R., Srikanth Prasad Tripathy, Vanaja Kumar, Frederick Quinn | | PLOS ONE. 2023; 18(3): e0282454 | | [Pubmed] | [DOI] | | | 2 |
Aromatic or Hetero-aromatic Directly Attached Tri and Tetrasubstituted
Methanes: New Chemical Entities as Anti-Infectives |
|
| Deblina Roy, Ritesh P. Thakare, Sidharth Chopra, Gautam Panda | | Current Medicinal Chemistry. 2023; 30(8): 974 | | [Pubmed] | [DOI] | | | 3 |
Discovery and Development of Antibacterial Agents: Fortuitous and
Designed |
|
| Ravleen Kaur, Pooja Rani, Atanas G. Atanasov, Qushmua Alzahrani, Reena Gupta, Bhupinder Kapoor, Monica Gulati, Pooja Chawla | | Mini-Reviews in Medicinal Chemistry. 2022; 22(7): 984 | | [Pubmed] | [DOI] | | | 4 |
Hit Compounds and Associated Targets in Intracellular Mycobacterium tuberculosis |
|
| Clement K. M. Tsui, Flavia Sorrentino, Gagandeep Narula, Alfonso Mendoza-Losana, Ruben Gonzalez del Rio, Esther Pérez Herrán, Abraham Lopez, Adama Bojang, Xingji Zheng, Modesto Jesus Remuiñán-Blanco, Yossef Av-Gay | | Molecules. 2022; 27(14): 4446 | | [Pubmed] | [DOI] | | | 5 |
AN INSIGHT INTO PRIVILEGED SCAFFOLDS IN TUBERCULOSIS: DEVELOPMENTAL ASPECTS AND IMPLICATIONS IN DRUG DESIGN |
|
| Rani. A. Shinde, Vasanti. M. Suvarna, Arundhati. N. Abhyankar | | Indian Drugs. 2022; 59(01): 7 | | [Pubmed] | [DOI] | | | 6 |
Bedaquiline: A Novel Diarylquinoline for Multidrug-Resistant Pulmonary Tuberculosis |
|
| Anuradha T Deshkar, Prashant A Shirure | | Cureus. 2022; | | [Pubmed] | [DOI] | | | 7 |
Recent developments, challenges and future prospects in advanced drug delivery systems in the management of tuberculosis |
|
| Nitin Verma, Vimal Arora, Rajendra Awasthi, Yinghan Chan, Niraj Kumar Jha, Komal Thapa, Talha Jawaid, Mehnaz Kamal, Gaurav Gupta, Gang Liu, Keshav Raj Paudel, Philip Michael Hansbro, Brian Gregory George Oliver, Sachin Kumar Singh, Dinesh Kumar Chellappan, Harish Dureja, Kamal Dua | | Journal of Drug Delivery Science and Technology. 2022; : 103690 | | [Pubmed] | [DOI] | | | 8 |
Emerging strategies in nanotechnology to treat respiratory tract infections: realizing current trends for future clinical perspectives |
|
| Minhua Chen, Zhangxuan Shou, Xue Jin, Yingjun Chen | | Drug Delivery. 2022; 29(1): 2442 | | [Pubmed] | [DOI] | | | 9 |
The respiratory lipoquinone, menaquinone, functions as an inducer of genes regulated by the Mycobacterium smegmatis repressor MSMEG_2295 |
|
| Anik Barman, Madhu Manti Patra, Sujoy K. Das Gupta | |
Microbiology
. 2022; 168(5) | | [Pubmed] | [DOI] | | | 10 |
The Changing Paradigm of Drug-Resistant Tuberculosis Treatment: Successes, Pitfalls, and Future Perspectives |
|
| Navisha Dookie, Senamile L. Ngema, Rubeshan Perumal, Nikita Naicker, Nesri Padayatchi, Kogieleum Naidoo | | Clinical Microbiology Reviews. 2022; | | [Pubmed] | [DOI] | | | 11 |
Nontuberculous Mycobacterial Resistance to Antibiotics and Disinfectants: Challenges Still Ahead |
|
| Samira Tarashi, Seyed Davar Siadat, Abolfazl Fateh, Fu-Ming Tsai | | BioMed Research International. 2022; 2022: 1 | | [Pubmed] | [DOI] | | | 12 |
A Test System for in vitro Screening Antimycobacterial Drug Candidates for MmpS5-MmpL5 Mediated Resistance |
|
| K. V. Shur, S. G. Frolova, N. I. Akimova, V. N. Danilenko, D. A. Maslov | | Russian Journal of Genetics. 2021; 57(1): 114 | | [Pubmed] | [DOI] | | | 13 |
The antimicrobial and immunomodulatory effects of Ionophores for the treatment of human infection |
|
| Gen Li, David M.P. De Oliveira, Mark J. Walker | | Journal of Inorganic Biochemistry. 2021; : 111661 | | [Pubmed] | [DOI] | | | 14 |
Efflux pumps in Mycobacterium tuberculosis and their inhibition to tackle antimicrobial resistance |
|
| Mark Laws, Peiqin Jin, Khondaker Miraz Rahman | | Trends in Microbiology. 2021; | | [Pubmed] | [DOI] | | | 15 |
Applicability of Chromatographic Co-Elution for Antibiotic Target Identification |
|
| Sina Schäkermann, Dominik Wüllner, Abdulkadir Yayci, Andrew Emili, Julia Elisabeth Bandow | | PROTEOMICS. 2021; 21(1): 2000038 | | [Pubmed] | [DOI] | | | 16 |
Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis |
|
| Jinmeng Li, Gaoyi Yang, Qingshan Cai, Yu Wang, Yingying Xu, Ruoying Zhang, Yazhen Lang, Xinjun Cai | | International Journal of Infectious Diseases. 2021; 110: 179 | | [Pubmed] | [DOI] | | | 17 |
Impact of drug-resistant tuberculosis treatment on hearing function in South African adults: Bedaquiline versus kanamycin |
|
| Katijah Khoza-Shangase, Marina Prodromos | | South African Journal of Communication Disorders. 2021; 68(1) | | [Pubmed] | [DOI] | | | 18 |
An evaluation of drug lag for new drugs approved by the Indian regulator relative to the United States, European Union, and Japanese regulatory agencies: A 15-year analysis (2004–2018) |
|
| Mahanjit Konwar, MiteshR Maurya, TusharB Nishandar, UrmilaM Thatte, NithyaJ Gogtay | | Perspectives in Clinical Research. 2021; 12(3): 159 | | [Pubmed] | [DOI] | | | 19 |
A review of current and promising nontuberculous mycobacteria antibiotics |
|
| Christophe R Cantelli, Alexandra Dassonville-Klimpt, Pascal Sonnet | | Future Medicinal Chemistry. 2021; 13(16): 1367 | | [Pubmed] | [DOI] | | | 20 |
Early Drug Development and Evaluation of Putative Antitubercular Compounds in the -Omics Era |
|
| Alina Minias, Lidia Zukowska, Ewelina Lechowicz, Filip Gasior, Agnieszka Knast, Sabina Podlewska, Daria Zygala, Jaroslaw Dziadek | | Frontiers in Microbiology. 2021; 11 | | [Pubmed] | [DOI] | | | 21 |
Knowledge Gaps in the Understanding of Antimicrobial Resistance in Canada |
|
| Kayley D. McCubbin, R. Michele Anholt, Ellen de Jong, Jennifer A. Ida, Diego B. Nóbrega, John P. Kastelic, John M. Conly, Matthias Götte, Tim A. McAllister, Karin Orsel, Ian Lewis, Leland Jackson, Graham Plastow, Hans-Joachim Wieden, Kathy McCoy, Myles Leslie, Joan L. Robinson, Lorian Hardcastle, Aidan Hollis, Nicholas J. Ashbolt, Sylvia Checkley, Gregory J. Tyrrell, André G. Buret, Elissa Rennert-May, Ellen Goddard, Simon J. G. Otto, Herman W. Barkema | | Frontiers in Public Health. 2021; 9 | | [Pubmed] | [DOI] | | | 22 |
Nanotechnology as a Novel Approach in Combating Microbes Providing an Alternative to Antibiotics |
|
| Bismillah Mubeen, Aunza Nayab Ansar, Rabia Rasool, Inam Ullah, Syed Sarim Imam, Sultan Alshehri, Mohammed M. Ghoneim, Sami I. Alzarea, Muhammad Shahid Nadeem, Imran Kazmi | | Antibiotics. 2021; 10(12): 1473 | | [Pubmed] | [DOI] | | | 23 |
Two Decades of TB Drug Discovery Efforts—What Have We Learned? |
|
| Balachandra Bandodkar, Radha Krishan Shandil, Jagadeesh Bhat, Tanjore S. Balganesh | | Applied Sciences. 2020; 10(16): 5704 | | [Pubmed] | [DOI] | | | 24 |
Bedaquiline: A Mini Review
|
|
| Nandhini Saravanabavan, Padmavathi Shanmuganathan, Manimekalai Kumarappan | | Annals of SBV. 2020; 8(1): 2 | | [Pubmed] | [DOI] | | | 25 |
Triple Mycobacterial ATP-synthase mutations impedes Bedaquiline binding: Atomistic and structural perspectives |
|
| Elliasu Y. Salifu, Clement Agoni, Fisayo A. Olotu, Mahmoud E.S. Soliman | | Computational Biology and Chemistry. 2020; 85: 107204 | | [Pubmed] | [DOI] | | | 26 |
Inhibition of Mycobacterium tuberculosis InhA: Design, synthesis and evaluation of new di-triclosan derivatives |
|
| Tom Armstrong, Malcolm Lamont, Alice Lanne, Luke J. Alderwick, Neil R. Thomas | | Bioorganic & Medicinal Chemistry. 2020; 28(22): 115744 | | [Pubmed] | [DOI] | | | 27 |
Screening of natural compounds that targets glutamate racemase of Mycobacterium tuberculosis reveals the anti-tubercular potential of flavonoids |
|
| Alka Pawar, Prakash Jha, Madhu Chopra, Uma Chaudhry, Daman Saluja | | Scientific Reports. 2020; 10(1) | | [Pubmed] | [DOI] | | | 28 |
Multitarget Approaches against Multiresistant Superbugs |
|
| Declan Alan Gray, Michaela Wenzel | | ACS Infectious Diseases. 2020; 6(6): 1346 | | [Pubmed] | [DOI] | | | 29 |
Mycobacterial tryptophan biosynthesis: A promising target for tuberculosis drug development? |
|
| Sara Consalvi, Cristina Scarpecci, Mariangela Biava, Giovanna Poce | | Bioorganic & Medicinal Chemistry Letters. 2019; 29(23): 126731 | | [Pubmed] | [DOI] | | | 30 |
Destination of aminoglycoside antibiotics in the ‘post-antibiotic era’ |
|
| Yoshiaki Takahashi, Masayuki Igarashi | | The Journal of Antibiotics. 2018; 71(1): 4 | | [Pubmed] | [DOI] | | | 31 |
The Emergence of Phenolic Glycans as Virulence Factors in Mycobacterium tuberculosis |
|
| Danielle D. Barnes, Mimmi L. E. Lundahl, Ed C. Lavelle, Eoin M. Scanlan | | ACS Chemical Biology. 2017; 12(8): 1969 | | [Pubmed] | [DOI] | |
|
|
|
|
|
|
|
|
